Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research at the Kennedy Institute reveals sub-populations of stromal cells with distinct functions in human fibrotic disease. These findings could inform development of more specific therapies with fewer off-target effects.

Dupuytren’s disease hand examination.
The study used human fibrotic tissue from Dupuytren’s disease, a common fibrotic condition of the hand

In their study, published in Nature Communications, the authors utilised single cell technologies to map different types of stromal cells and their relationship to each other in human tissues affected by fibrosis. Their approach revealed several distinct populations of stromal cells with different functional roles.

Fibrotic disorders arise from poorly regulated tissue repair processes, leading to a build-up of collagen and scar tissue that impairs organ function. These diseases are some of the most devastating and poorly treated conditions in the Western world, yet effective therapeutics are often lacking. 

Lead author Jagdeep Nanchahal said: "Animal models fail to replicate many aspects of human fibrosis and there remains limited availability of well-characterised patient samples at developing stages of disease. Our study exclusively used human fibrotic tissue from Dupuytren's disease, a common fibrotic condition of the hand, to profile an entire human fibrotic ecosystem at single cell resolution."


"We were able to build a single cell atlas of human fibrosis-promoting stromal cells and describe functionally distinct types and states. This division of labour between fibrotic stromal cells will allow us to form a powerful translational resource to help inform development of treatments and represents an exciting avenue for future research," he concluded.

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research Trauma

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.